SalBenz-1-OT20

SalBenz-1-OT20 is an experimental **peptide-drug conjugate** reported in preclinical academic research as a glioblastoma-targeting anticancer agent. The construct links a **salicylanilide 4-formylbenzoate** warhead, designated SalBenz-1, to the **oligotuftsin carrier peptide OT20** with sequence [TKPKG]4 through an **oxime bond**. OT20 was used as a **neuropilin receptor-binding targeting peptide** intended to enhance uptake into glioblastoma cells, while the salicylanilide payload provides the cytotoxic anticancer activity. In U87 human glioblastoma cells, the conjugate reduced cell viability and was associated with **autophagy-related cell death**, although the publication notes that autophagy induction was more limited than with unconjugated SalBenz-1. The agent appears to be a **research-stage compound** from an academic medicinal chemistry study rather than a clinically developed or commercial pharmaceutical product.

Other names

salicylanilide 4-formylbenzoate oligotuftsin conjugatesalicylanilide4-formylbenzoate oligotuftsin conjugatesalicylanilide-4-formylbenzoate oligotuftsin conjugateSalBenz-1 conjugated to OT20SalBenz1 conjugated to OT20SalBenz 1 conjugated to OT20